QV Bioelectronics

QV Bioelectronics is developing an implanted electrotherapy device to increase the life expectancy of patients with glioblastoma, the most common primary brain cancer. Electrotherapy is an approved treatment that has been able to extend patient survival, however with only cumbersome and heavy externally-applied devices

QV Bioelectronics is a company in human health based in United Kingdom, founded in 2018.

Profile

QV Bioelectronics is developing an implanted electrotherapy device for the treatment of glioblastoma (GBM). GBM is the most most common primary adult brain cancer, and with no cure and limited treatments available, patients are only expected to survive 14 months post-diagnosis. Our innovative electrode technology will allow us to double the life expectancy of patients by delivering electrotherapeutic currents 24/7 without impacting a patient’s quality of life.

Its activity falls under human health; the profile below is assembled from public directory data.

United Kingdom is where the company is located.

It is recorded at the SOSV portfolio company stage.

The company reports a headcount in the 2-10 range.

Total disclosed funding stands at about $195K.

Website: qvbio.co.uk